new glp 1 drug retatrutide Some Providers Prescribe Unapproved for Weight Loss at Alarming Rate Retatrutide for weight loss: Study

1998 Jun 15 [cited 2025 Apr 19]

Dohnal, V., Wu, Q

6 Results from a systematic review and meta-analysis study showed that following discontinuation of weight management medications: Patients are estimated to return to baseline weight within 1.7 years 1,** Results from that same study also highlighted that following discontinuation of weight management medications: Cardiometabolic benefits may be lost, with markers estimated to return to baseline within 1.4 years 1,** Ongoing obesity treatment is needed for maintaining weight loss and improvements in cardiometabolic markers 4 Addressing Discontinuation Starts With Understanding What May Influence Adherence and Persistence 5 Long-term adherence is shaped by multiple, interconnected factorsand ongoing research continues to explore how challenges may interact over time

The My Spektrum site is dedicated to product registration, firmware updates, and downloads for your Spektrum products

Neuropathy or neurological disease: Although evidence is mixed, injections are often given when deficiency is linked to nerve pain or cognitive symptoms